Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Heinz Gisslinger, Thamer Sliwa et al.|American Journal of Hematology|2017Cited by 66
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera StudVeronika Buxhofer‐Ausch, Richard Greil, Heinz Gisslinger et al.|Blood|2015Cited by 1
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera PatientHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2015Cited by 0
Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological DiagnosisGeorg Jeryczynski, Heinz Gisslinger, Albert Woelfler et al.|Blood|2016Cited by 0